Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Primary Mediastinal Large B Cell Lymphoma Clinical Trial

Official title:

A Phase II Study on the Safety and Efficacy of Zanubrutinib Combined With Tislelizumab in the Treatment of Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma and Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04705129
• Other study ID #: RJ-PMBCL-1
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2021
• Est. completion date: January 1, 2024

Study information

• Verified date: March 2021
• Source: Ruijin Hospital
• Contact: Weili Zhao, PhD, MD
• Phone: +862164370045
• Email: zwl_trial[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is to investigate the safety and efficacy of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma.

Description:

R-CHOP regimen is the first-line therapy in DLBCL which greatly improved the efficacy of diffuse large B-cell lymphoma (DLBCL) and achieved good long-term survival. However, among DLBCL patients treated with R-CHOP, EBV+ had a lower 5-year OS than EBV- patients (65% vs 82%). For primary mediastinal large B-cell lymphoma (PMBCL), although the initial treatment has a better prognosis than DLBCL, there are still 10% to 30% of PMBCL patients with primary refractory or relapsed disease, and the prognosis is poor.

Zanubrutinib combined with Tislelizumab has been proved efficient in relapsed or refractory NHLs, with ORR rate 37%, CR rate of 16.7%. This phase II, prospective, open-label, single-arm study will evaluate the efficacy and safety of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: January 1, 2024
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Pathologically confirmed diffuse large B-cell lymphoma, EBV positive and primary mediastinal large B-cell lymphoma

• Have received at least one prior standard therapy line including Rituximab and anthracyclines.

• Age=18

• ECOG 0,1,2

• Imaging accessible lesions

• Life expectancy>3 months

• Informed consented

Exclusion Criteria:

• Have received systemic or local treatment including chemotherapy within three weeks before enrollment

• Chronic or active infectious diseases that require systemic antibiotics, antifungals or antiviral therapy

• Lab at enrollment (Unless caused by lymphoma) : Neutrophile<1.0*10^9/L , Hemoglobin<80g/L, Platelet<50*10^9/L, ALT or AST >2*ULN,AKP or bilirubin >1.5*ULN Creatinine>1.5*ULN

• Other uncontrollable medical condition that may that may interfere the participation of the study Not able to comply to the protocol for mental or other unknown reasons

• HIV infection

• If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA, DNA positive patients cannot be enrolled

• Previously received BTK inhibitor or anti-PD-1/PD-L1 treatment

• History of active autoimmune disease or severe autoimmune disease

• Need to be given corticosteroids (dose equivalent to prednisone >20 mg/day) or other immunosuppressive agents within 14 days before the study drug administration

• A history of interstitial lung disease or non-infectious pneumonia, except for those caused by radiotherapy

• Need strong cytochrome P450 (CYP) 3A inhibitor or inducer drug treatment

• Received live vaccination within 28 days before the first dose of study drug

• Patients who can receive hematopoietic stem cell transplantation, and if the subject has received allogeneic stem cell transplantation within 6 months before the first administration of the study drug or has active graft-versus-host disease requiring continuous immunosuppressive therapy

• Have received any experimental drug within 28 days, or the toxicity of any previous chemotherapy has not been relieved to = Grade 1

• History of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, unless recovered for at least 2 years

• Have a history of other active malignancies within 2 years before entering the study, excluding cervical cancer in situ, local basal cell or squamous cell skin cancer that has been cured by adequate treatment; or the previous malignant tumor is localized and has undergone local radical treatment Treatment (surgery or other forms)

• Pregnant or nursing period

• Men or women who are fertile but refuse to take appropriate contraceptive measures, unless they have been surgically sterilized

Related Conditions & MeSH terms

• EBV-Positive DLBCL, Nos
• Lymphoma
• Lymphoma, B-Cell
• Primary Mediastinal Large B Cell Lymphoma

Intervention

Drug:
• Zanubrutinib
160mg Bid, D1-21, po
• Tislelizumab
200mg, D1, ivgtt

Locations

Country	Name	City	State
China	Ruijin Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The significance of biomarkers in tissue and plasma including cfDNA, PD-1,PD-L1	Dynamic change of the expression of PD-1, PD-L1	through study completion,an average of 2 years
Primary	complete response rate	Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria	21 days after 6 cycles of treatment (each cycle is 21 days)
Secondary	progression free survival	Progression-free survival was defined as the time from the date of diagnosis until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria,or death from any cause, whichever occurred first.	2 year
Secondary	overall survival	Overall survival was defined as the time from the date of diagnosis to the date of death from any cause. Reported is the percentage of participants with event. of disease progression or relapse, using 2014 Lugano criteria,or death from any cause, whichever occurred first.	2 year
Secondary	Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0	An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events	Up to 30 days after completion of study treatment